Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinically significant drug interactions with antituberculosis agents

J M Grange1, P A Winstanley, P D Davies

  • 1Department of Microbiology, National Heart and Lung Institute, London, England.

Drug Safety
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot plant study of alternative filter media for rapid gravity filtration.

Water science and technology : a journal of the International Association on Water Pollution Research·2012
Same author

Immune protection against tuberculosis--when is immunotherapy preferable to vaccination?

Tuberculosis (Edinburgh, Scotland)·2011
Same author

Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria.

Clinical pharmacology and therapeutics·2010
Same author

Incorporation of an additional glycosylation site enhances expression of functional human gonadotropin-releasing hormone receptor.

Endocrine·2010
Same author

From virus to cosmology.

Journal of the Royal Society of Medicine·2010
Same author

From virus to cosmology.

Journal of the Royal Society of Medicine·2010
Same journal

Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution Instruments.

Drug safety·2026
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
See all related articles

Drug interactions are a growing concern in tuberculosis treatment, especially with multidrug-resistant strains and HIV/AIDS co-infections. Rifampicin and quinolones pose significant risks due to their effects on drug metabolism. Careful management is crucial.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Drug Interactions

Background:

  • Standard tuberculosis treatments are generally safe, but drug resistance necessitates complex regimens.
  • Emerging multidrug-resistant tuberculosis and HIV/AIDS co-infections increase the risk of drug interactions.
  • Newer drugs and co-treatments for opportunistic infections further complicate medication management.

Purpose of the Study:

  • To review and highlight the significant drug interactions associated with tuberculosis treatment.
  • To emphasize the challenges posed by multidrug-resistant tuberculosis and HIV/AIDS co-infections.
  • To inform clinicians about potential drug interactions with first-line and newer antituberculosis agents.

Main Methods:

  • Literature review of drug interactions in tuberculosis therapy.

Related Experiment Videos

  • Analysis of the pharmacokinetic properties of key antituberculosis drugs.
  • Examination of drug-drug interactions in the context of HIV/AIDS and co-infections.

    • Main Results:

    • First-line antituberculosis drugs have few interactions, but rifampicin is a potent inducer of cytochrome P450 enzymes.
    • Rifampicin significantly interacts with oral contraceptives, corticosteroids, anticoagulants, and cyclosporine.
    • Quinolones, used for multidrug-resistant tuberculosis, inhibit cytochrome isoenzymes, affecting metabolism of other drugs.

    Conclusions:

    • Rifampicin's enzyme-inducing properties present major drug interaction risks.
    • Quinolones' enzyme-inhibiting effects add complexity to managing co-medications.
    • Clinical vigilance and careful regimen selection are essential to mitigate drug interaction risks in tuberculosis patients.